Cleerly, the company creating a new standard of care for heart disease, launched today with $43 million in Series B funding and unveiled its first-of-its-kind digital care pathway solution for heart attack prevention. The financing, which was led by Vensana Capital with participation from LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures, and existing investors, brings Cleerly’s total funding to $54 million.

Cleerly is the company creating a new standard of care for heart disease. Through value-based precision diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Headquartered in New York City and led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.

Cleerly Launches With $43 Million Series B To Provide A New Standard Of Care For The Leading Cause Of Death – Heart Disease

Description

Company Information

Cleerly Launches With $43 Million Series B To Provide A New Standard Of Care For The Leading Cause Of Death – Heart Disease

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information